Minerva Neurosciences (NERV)

• Market cap: $27.8M
• 1 day: -1.97%
• 5 days: 4.74%
• 1 month: 5.29%
• 3 months: 81.74%
• 6 months: 121.11%
• Year to date: 73.04%
• 1 year: 87.74%
• 5 years: -79.78%
• 10 years: -91.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 8